文献速递膀胱癌与上尿路尿路上皮癌

利用条件重编程患者来源细胞进行膀胱癌个体化药物敏感性筛查

Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells.
PubMed 文献 · Eur Urol · 2019-06-28

研究建立6例不同组织学和分期的膀胱癌条件重编程(CR)细胞培养,其中4例成功扩增用于基因组、转录组和蛋白表达谱分析并与原发肿瘤比较。2例(尿路上皮癌和小细胞神经内分泌癌)与原发肿瘤对应良好并接受药物敏感性筛查,均对标准膀胱癌化疗药及紫杉烷类、拓扑异构酶和蛋白酶体抑制剂敏感,小细胞神经内分泌癌细胞还对他汀类敏感。结论认为CR细胞是个体化药物敏感性检测的可行平台,可能补充膀胱癌个体化治疗策略。

要点

  • 6例膀胱癌中4例成功建立条件重编程培养并完成分子谱分析。
  • 2例培养(尿路上皮癌和小细胞神经内分泌癌)与原发肿瘤对应良好。
  • 两例培养均对顺铂、吉西他滨等标准膀胱癌化疗药敏感。

核心结论

  • 在确认代表性和来源后,条件重编程细胞是个体化药物敏感性检测的可行平台,可能补充膀胱癌个体化治疗策略。

研究设计与样本

  • 研究从6例不同组织学和分期的膀胱癌肿瘤建立条件重编程(CR)培养,其中4例成功扩增用于基因组、转录组和蛋白表达谱分析并与原发肿瘤比较。

主要发现

  • 4例CR培养中2例(尿路上皮癌和小细胞神经内分泌癌)与原发肿瘤对应良好,并接受药物敏感性筛查以识别各自肿瘤的新药。
  • 两例培养均对标准膀胱癌化疗药(如顺铂和吉西他滨)以及紫杉烷类、拓扑异构酶抑制剂和蛋白酶体抑制剂等常规药物敏感。
  • 小细胞神经内分泌癌细胞还对他汀类(如阿托伐他汀和匹伐他汀)敏感。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many patients with muscle-invasive bladder cancer (BC) are either ineligible for or do not benefit from cisplatin-based chemotherapy, and there is an unmet need to estimate individuals' drug sensitivities. We investigated the suitability of conditionally reprogrammed (CR) cells for the characterization of BC properties and their feasibility for personalized drug sensitivity screening. The CR cultures were established from six BC tumors with varying histology and stage. Four cultures were successfully propagated for genomic, transcriptomic, and protein expression profiling and compared to the parental tumors. Two out of four CR cultures (urothelial carcinoma and small cell neuroendocrine carcinoma [SmCC]) corresponded well to their parental tumors and underwent drug sensitivity screening to identify novel drugs for the respective tumors. Both cultures were sensitive to standard BC chemotherapy agents (eg cisplatin and gemcitabine) and to conventional drugs such as taxanes and inhibitors of topoisomerase and proteasome. The SmCC cells were also sensitive to statins (eg, atorvastatin and pitavastatin). In summary, after confirming their representativeness and origin, we conclude that CR cells are a feasible platform for personalized drug sensitivity testing and might thus add to the approaches used to personalize BC treatment strategies. PATIENT SUMMARY: We investigated the conditional reprogramming method for generating patient-derived bladder cancer cell cultures and studied their feasibility for planning personalized treatment strategies.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kettunen K, Boström PJ, Lamminen T, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol. 2019. PMID: 31256944. doi:10.1016/j.eururo.2019.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。